AUTHOR=He Wen , Ji Yazheng , Wei Xiating , Wang Fan , Xu Feng , Lu Chengyi , Ma Qianqian , Wang Kai TITLE=Eye Movement Technique to Improve Executive Function in Patients With Stroke: A Randomized Controlled Trial JOURNAL=Frontiers in Neurology VOLUME=12 YEAR=2021 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.599850 DOI=10.3389/fneur.2021.599850 ISSN=1664-2295 ABSTRACT=

Objective: To investigate the efficacy of eye movement technique for the treatment of executive dysfunction of patients with stroke.

Methods: This was a prospective, single-blinded, randomized, controlled, single-center clinical trial conducted from June 2018 to December 2019 in patients with stroke. The patients were randomized 1:1 to the routine (conventional management) and eye-move group (routine management plus eye movement technique: 5-min goal management training, 5-min computer-aided working memory, and 10 min of inhibitory control training and set conversion training). The intervention lasted 6 weeks, followed by a 4-week follow-up. The primary endpoint was the Behavioral Assessment of the Dysexecutive Syndrome (BADS) score. The secondary endpoints mainly included the Montreal Cognitive Assessment (MoCA), Wisconsin Card Sorting Test (WCST), and modified Barthel Index (MBI) scores.

Results: Sixty-four patients were enrolled (32/group). After the 6-week intervention, the BADS and WCST scores of the eye-move group were significantly improved than those of the routine group (all P < 0.05), but the effects were attenuated in certain subscores after follow-up (all P > 0.05). The MoCA and MBI scores of the eye-move group were significantly higher, and the reaction time was significantly lower than those of the routine group at 4 weeks after the intervention (all P < 0.05). After follow-up, the MBI scores of the eye-move group were still higher than that of the routine group (P < 0.001), but there were no differences for MoCA scores and reaction time (both P > 0.05).

Conclusion: The eye movement technique could improve the executive function of patients with stroke. These results have to be confirmed.

This was a prospective, single-blinded, randomized, controlled, single-center clinical trial (ChiCTR2000036393).

Clinical Trial Registration: [www.chictr.org.cn], identifier [ChiCTR2000036393].